ProQR (PRQR)
NASDAQ:PRQR
Want to see PRQR full AI Analyst Report?
PRQR Stock Chart & Stats
$1.99
-$0.10(-3.77%)
At close: 4:00 PM EST
$1.99
-$0.10(-3.77%)
Day’s Range― - ―
52-Week Range$1.33 - $3.10
Previous CloseN/A
Volume75.97K
Average Volume (3M)534.76K
Market Cap
$158.04M
Enterprise Value$75.28M
Total Cash (Recent Filing)$81.17M
Total Debt (Recent Filing)$13.70M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Jul 30, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding105,361,060
10 Day Avg. Volume796,312
30 Day Avg. Volume534,757
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.67
Price to Sales (P/S)11.85
P/FCF Ratio-3.50
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue5.60
Enterprise Value/Gross Profit6.24
Enterprise Value/Ebitda-1.73
Forecast
1Y Price Target
$8.20Price Target Upside312.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$20.65M
Bulls Say, Bears Say
Bulls Say
Cash RunwayA cash balance covering operations into mid-2027 gives management multi-quarter runway to advance Phase 1/2 activities, generate target-engagement data and pursue AI-enabled discovery milestones without immediate financing. This durable liquidity window supports clinical execution and program de-risking.
Platform & Pipeline ExpansionProQR is broadening its Axiomer RNA-editing platform with multiple development candidates and an AI partnership with Ginkgo. This strengthens long-term competitive advantage by increasing candidate throughput, shortening discovery timelines and creating multiple clinical catalysts beyond a single asset.
Strengthened Governance And ExpertiseAdding a seasoned drug-development executive and reconstituting committees enhances clinical and regulatory oversight. Strong external governance and industry experience improve strategic decision-making and execution capacity as the company transitions deeper into clinical development.
Bears Say
Revenue Decline & Negative MarginsSustained revenue contraction alongside extreme negative operating and net margins indicate the business cannot cover operating costs from sales. Even with high gross margins, fixed R&D and SG&A drive persistent losses, making long-term viability contingent on successful clinical outcomes or new revenue streams.
High Cash Burn And Negative Cash FlowConsistent negative operating and free cash flow means the company is not self-funding and remains reliant on external capital. Continued high burn increases refinancing risk, could force dilutive financing, and constrains strategic optionality if clinical or partnership milestones slip.
Equity Erosion & Negative ReturnsDeclining shareholders' equity and a large negative ROE reflect ongoing value destruction from losses. Although leverage is moderate, diminished equity reduces the balance-sheet buffer versus adverse outcomes and limits flexibility for non-dilutive financing, increasing vulnerability if losses persist.
ProQR News
PRQR FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $1.33 and its highest was $3.10 in the past 12 months.
What is ProQR’s market cap?
ProQR’s market cap is $158.04M.
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is Jul 30, 2026 which is in 52 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on May 12, 2026. The company reported -$0.151 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.012.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -0.14.
How many shares outstanding does ProQR have?
ProQR has 105,361,060 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -$0.151 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went down -0.621%.
Which hedge fund is a major shareholder of ProQR?
Currently, no hedge funds are holding shares in PRQR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProQR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.20 (312.06% Upside)
$8.20 (312.06% Upside)
Hedge Fund Trend
Increased
By 91.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.08%
12-Months-Change
Fundamentals
Return on Equity
-86.47%
Trailing 12-Months
Asset Growth
-30.36%
Trailing 12-Months
Company Description
ProQR
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
PRQR Stock 12 Month Forecast
Average Price Target
$8.20
▲(312.06% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.85% Mutual Funds
23.37% Other Institutional Investors
74.37% Public Companies and
Individual Investors